{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T17:43:32Z","timestamp":1795110212607,"version":"4.10.3"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004410","name":"T\u00fcrkiye Bilimsel ve Teknolojik Ara\u015ftirma Kurumu","doi-asserted-by":"publisher","award":["117Z227"],"award-info":[{"award-number":["117Z227"]}],"id":[{"id":"10.13039\/501100004410","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004410","name":"T\u00fcrkiye Bilimsel ve Teknolojik Ara\u015ftirma Kurumu","doi-asserted-by":"publisher","award":["117Z227"],"award-info":[{"award-number":["117Z227"]}],"id":[{"id":"10.13039\/501100004410","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004412","name":"T\u00fcrkiye Bilimler Akademisi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004412","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005771","name":"Dokuz Eyl\u00fcl \u00dcniversitesi","doi-asserted-by":"publisher","award":["TSA-2024-3533"],"award-info":[{"award-number":["TSA-2024-3533"]}],"id":[{"id":"10.13039\/501100005771","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Malignant pleural mesothelioma (MPM) is a rare yet highly aggressive malignancy with a severe prognosis. Compounded by the lack of effective treatment modalities, MPM remains a formidable health challenge. Therefore, the identification of actionable liabilities is critical for advancing precision medicine to combat this lethal disease. Here, we exploit an unbiased genome-wide CRISPR screen, integrating and cross-comparing three MPM cell lines with nonmalignant mesothelial cells, to selectively map the gene targets whose depletion indicates a common dependency in MPM cells. This systematic approach unveils a cohort of verifiable genes, among which BUB1, a mitotic checkpoint serine\/threonine kinase, emerges as a high-confidence hit in cancer cells. Cellular and molecular studies demonstrate that genetic depletion or pharmacological inhibition of BUB1 profoundly impairs MPM cell survival and growth while inducing G2\/M cell cycle arrest, cellular senescence, and apoptosis, and attenuating functional hallmarks of aggressive cancer cells. Transcriptomic profiling of BUB1-depleted cells discloses differential gene expression signatures congruent with cell fate phenotypes, including the reprogramming of mitotic network genes. Mechanistically, BUB1 is indispensable for the proper localization of essential mitotic regulators MAD1, MAD2, and Shugoshin (SGO1), thereby ensuring the functionality of the spindle assembly checkpoint (SAC). Furthermore, BUB1 ablation leads to cytokinesis failure and multinucleation, a phenotype characterized by the downregulation of CDC20, Cyclin A, and Cyclin B, and a reciprocal upregulation of the cyclin-dependent kinase inhibitor p21. Clinically, MPM tumors exhibit elevated levels of BUB1, and high BUB1 expression is associated with shorter patient survival. Our novel findings accentuate comparative CRISPR screens as a powerful platform to explore tumor cell-selective gene essentiality and propose BUB1 kinase as a potential marker and druggable vulnerability with therapeutic implications for MPM.<\/jats:p>","DOI":"10.1038\/s41419-025-07587-z","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T16:24:20Z","timestamp":1743783860000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Genome-wide CRISPR screen identifies BUB1 kinase as a druggable vulnerability in malignant pleural mesothelioma"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5761-7760","authenticated-orcid":false,"given":"Ece","family":"Cakiroglu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2310-8829","authenticated-orcid":false,"given":"Sude","family":"Eris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozden","family":"Oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6706-1375","authenticated-orcid":false,"given":"G\u00f6khan","family":"Karak\u00fclah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3963-2294","authenticated-orcid":false,"given":"Serif","family":"Senturk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,3]]},"reference":[{"key":"7587_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"7587_CR2","doi-asserted-by":"publisher","first-page":"743","DOI":"10.2147\/CLEP.S105396","volume":"8","author":"JL Beebe-Dimmer","year":"2016","unstructured":"Beebe-Dimmer JL, Fryzek JP, Yee CL, Dalvi TB, Garabrant DH, Schwartz AG, et al. Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)-Medicare investigation of treatment patterns and overall survival. Clin Epidemiol. 2016;8:743\u201350.","journal-title":"Clin Epidemiol"},{"key":"7587_CR3","doi-asserted-by":"publisher","first-page":"6342","DOI":"10.3390\/ijms21176342","volume":"21","author":"E Cakiroglu","year":"2020","unstructured":"Cakiroglu E, Senturk S. Genomics and functional genomics of malignant pleural mesothelioma. Int J Mol Sci. 2020;21:6342.","journal-title":"Int J Mol Sci"},{"key":"7587_CR4","doi-asserted-by":"publisher","first-page":"e161","DOI":"10.1016\/S1470-2045(18)30100-1","volume":"19","author":"A Scherpereel","year":"2018","unstructured":"Scherpereel A, Wallyn F, Albelda SM, Munck C. Novel therapies for malignant pleural mesothelioma. Lancet Oncol. 2018;19:e161\u201372.","journal-title":"Lancet Oncol"},{"key":"7587_CR5","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.critrevonc.2016.08.011","volume":"107","author":"G Bronte","year":"2016","unstructured":"Bronte G, Incorvaia L, Rizzo S, Passiglia F, Galvano A, Rizzo F, et al. The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet? Crit Rev Oncol Hematol. 2016;107:20\u201332.","journal-title":"Crit Rev Oncol Hematol"},{"key":"7587_CR6","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.3389\/fonc.2019.01519","volume":"9","author":"F Nicolini","year":"2019","unstructured":"Nicolini F, Bocchini M, Bronte G, Delmonte A, Guidoboni M, Crin\u00f2 L, et al. Malignant pleural mesothelioma: state-of-the-art on current therapies and promises for the future. Front Oncol. 2019;9:1519.","journal-title":"Front Oncol"},{"key":"7587_CR7","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41576-021-00409-w","volume":"23","author":"L Przybyla","year":"2022","unstructured":"Przybyla L, Gilbert LA. A new era in functional genomics screens. Nat Rev Genet. 2022;23:89\u2013103.","journal-title":"Nat Rev Genet"},{"key":"7587_CR8","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/nrg3899","volume":"16","author":"O Shalem","year":"2015","unstructured":"Shalem O, Sanjana NE, Zhang F. High-throughput functional genomics using CRISPR-Cas9. Nat Rev Genet. 2015;16:299\u2013311.","journal-title":"Nat Rev Genet"},{"key":"7587_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.870745","volume":"10","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Song C, Wang L, Jiang H, Zhai Y, Wang Y, et al. Zombies never die: the double life Bub1 lives in mitosis. Front Cell Dev Biol. 2022;10. 870745.","journal-title":"Front Cell Dev Biol"},{"key":"7587_CR10","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nbt.3437","volume":"34","author":"JG Doench","year":"2016","unstructured":"Doench JG, Fusi N, Sullender M, Hegde M, Vaimberg EW, Donovan KF, et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat Biotechnol. 2016;34:184\u201391.","journal-title":"Nat Biotechnol"},{"key":"7587_CR11","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1158\/0008-5472.CAN-04-4567","volume":"66","author":"R Jagadeeswaran","year":"2006","unstructured":"Jagadeeswaran R, Ma PC, Seiwert TY, Jagadeeswaran S, Zumba O, Nallasura V, et al. Functional analysis of c-Met\/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res. 2006;66:352\u201361.","journal-title":"Cancer Res"},{"key":"7587_CR12","doi-asserted-by":"publisher","first-page":"3884","DOI":"10.1073\/pnas.82.11.3884","volume":"82","author":"JF Lechner","year":"1985","unstructured":"Lechner JF, Tokiwa T, LaVeck M, Benedict WF, Banks-Schlegel S, Yeager H, et al. Asbestos-associated chromosomal changes in human mesothelial cells. Proc Natl Acad Sci USA. 1985;82:3884\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"7587_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0554-4","volume":"15","author":"W Li","year":"2014","unstructured":"Li W, Xu H, Xiao T, Cong L, Love MI, Zhang F, et al. MAGeCK enables robust identification of essential genes from genome-scale CRISPR\/Cas9 knockout screens. Genome Biol. 2014;15. 554.","journal-title":"Genome Biol"},{"key":"7587_CR14","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/j.cell.2015.11.015","volume":"163","author":"T Hart","year":"2015","unstructured":"Hart T, Chandrashekhar M, Aregger M, Steinhart Z, Brown KR, MacLeod G, et al. High-resolution CRISPR screens reveal fitness genes and genotype-specific cancer liabilities. Cell. 2015;163:1515\u201326.","journal-title":"Cell"},{"key":"7587_CR15","doi-asserted-by":"publisher","first-page":"W216","DOI":"10.1093\/nar\/gkac194","volume":"50","author":"BT Sherman","year":"2022","unstructured":"Sherman BT, Hao M, Qiu J, Jiao X, Baseler MW, Lane HC, et al. DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res. 2022;50:W216\u201321.","journal-title":"Nucleic Acids Res"},{"key":"7587_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-021-02540-7","volume":"22","author":"JM Dempster","year":"2021","unstructured":"Dempster JM, Boyle I, Vazquez F, Root DE, Boehm JS, Hahn WC, et al. Chronos: a cell population dynamics model of CRISPR experiments that improves inference of gene fitness effects. Genome Biol. 2021;22. 343.","journal-title":"Genome Biol"},{"key":"7587_CR17","doi-asserted-by":"publisher","first-page":"6428","DOI":"10.1002\/cam4.4161","volume":"10","author":"N Miralaei","year":"2021","unstructured":"Miralaei N, Majd A, Ghaedi K, Peymani M, Safaei M. Integrated pan-cancer of AURKA expression and drug sensitivity analysis reveals increased expression of AURKA is responsible for drug resistance. Cancer Med. 2021;10:6428\u201341.","journal-title":"Cancer Med"},{"key":"7587_CR18","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1002\/1878-0261.12066","volume":"11","author":"L Wang","year":"2017","unstructured":"Wang L, Arras J, Katsha A, Hamdan S, Belkhiri A, Ecsedy J, et al. Cisplatin-resistant cancer cells are sensitive to Aurora kinase A inhibition by alisertib. Mol Oncol. 2017;11:981\u201395.","journal-title":"Mol Oncol"},{"key":"7587_CR19","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1002\/med.21399","volume":"36","author":"M Yan","year":"2016","unstructured":"Yan M, Wang C, He B, Yang M, Tong M, Long Z, et al. Aurora-A kinase: a potent oncogene and target for cancer therapy. Med Res Rev. 2016;36:1036\u201379.","journal-title":"Med Res Rev"},{"key":"7587_CR20","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.drudis.2019.12.001","volume":"25","author":"S Tadesse","year":"2020","unstructured":"Tadesse S, Anshabo AT, Portman N, Lim E, Tilley W, Caldon CE, et al. Targeting CDK2 in cancer: challenges and opportunities for therapy. Drug Discov Today. 2020;25:406\u201313.","journal-title":"Drug Discov Today"},{"key":"7587_CR21","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.tranon.2016.08.007","volume":"9","author":"J Wang","year":"2016","unstructured":"Wang J, Yang T, Xu G, Liu H, Ren C, Xie W, et al. Cyclin-dependent kinase 2 promotes tumor proliferation and induces radio resistance in glioblastoma. Transl Oncol. 2016;9:548\u201356.","journal-title":"Transl Oncol"},{"key":"7587_CR22","first-page":"233","volume":"13","author":"H Yamamoto","year":"1998","unstructured":"Yamamoto H, Monden T, Miyoshi H, Izawa H, Ikeda K, Tsujie M, et al. Cdk2\/cdc2 expression in colon carcinogenesis and effects of cdk2\/cdc2 inhibitor in colon cancer cells. Int J Oncol. 1998;13:233\u20139.","journal-title":"Int J Oncol"},{"key":"7587_CR23","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s00428-017-2237-5","volume":"471","author":"H Xu","year":"2017","unstructured":"Xu H, Miao ZF, Wang ZN, Zhao TT, Xu YY, Song YX, et al. HCRP1 downregulation confers poor prognosis and induces chemoresistance through regulation of EGFR-AKT pathway in human gastric cancer. Virchows Arch. 2017;471:743\u201351.","journal-title":"Virchows Arch"},{"key":"7587_CR24","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.bbrc.2016.06.046","volume":"477","author":"W Yang","year":"2016","unstructured":"Yang W, Wang JG, Wang Q, Qin Y, Lin X, Zhou D, et al. Decreased HCRP1 promotes breast cancer metastasis by enhancing EGFR phosphorylation. Biochem Biophys Res Commun. 2016;477:222\u20138.","journal-title":"Biochem Biophys Res Commun"},{"key":"7587_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14370","volume":"8","author":"S Senturk","year":"2017","unstructured":"Senturk S, Shirole NH, Nowak DG, Corbo V, Pal D, Vaughan A, et al. Rapid and tunable method to temporally control gene editing based on conditional Cas9 stabilization. Nat Commun. 2017;8:14370.","journal-title":"Nat Commun"},{"key":"7587_CR26","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/32688","volume":"392","author":"DP Cahill","year":"1998","unstructured":"Cahill DP, Lengauer C, Yu J, Riggins GJ, Willson JK, Markowitz SD, et al. Mutations of mitotic checkpoint genes in human cancers. Nature. 1998;392:300\u20133.","journal-title":"Nature"},{"key":"7587_CR27","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1083\/jcb.201012035","volume":"193","author":"RM Ricke","year":"2011","unstructured":"Ricke RM, Jeganathan KB, van Deursen JM. Bub1 overexpression induces aneuploidy and tumor formation through Aurora B kinase hyperactivation. J Cell Biol. 2011;193:1049\u201364.","journal-title":"J Cell Biol"},{"key":"7587_CR28","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.3390\/cancers12082206","volume":"12","author":"Y Fujibayashi","year":"2020","unstructured":"Fujibayashi Y, Isa R, Nishiyama D, Sakamoto-Inada N, Kawasumi N, Yamaguchi J, et al. Aberrant BUB1 overexpression promotes mitotic segregation errors and chromosomal instability in multiple myeloma. Cancers. 2020;12:2206.","journal-title":"Cancers"},{"key":"7587_CR29","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/1078-0432.CCR-18-0628","volume":"25","author":"G Siemeister","year":"2019","unstructured":"Siemeister G, Mengel A, Fern\u00e1ndez-Montalv\u00e1n AE, Bone W, Schr\u00f6der J, Zitzmann-Kolbe S, et al. Inhibition of BUB1 kinase by BAY 1816032 sensitizes tumor cells toward taxanes, ATR, and PARP inhibitors in vitro and in vivo. Clin Cancer Res. 2019;25:1404\u201314.","journal-title":"Clin Cancer Res"},{"key":"7587_CR30","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.12187","volume":"5","author":"AP Baron","year":"2016","unstructured":"Baron AP, von Schubert C, Cubizolles F, Siemeister G, Hitchcock M, Mengel A, et al. Probing the catalytic functions of Bub1 kinase using the small molecule inhibitors BAY-320 and BAY-524. eLife. 2016;5:e12187.","journal-title":"eLife"},{"key":"7587_CR31","doi-asserted-by":"publisher","first-page":"D1074","DOI":"10.1093\/nar\/gkaa1059","volume":"49","author":"C Mitsopoulos","year":"2021","unstructured":"Mitsopoulos C, Di Micco P, Fernandez EV, Dolciami D, Holt E, Mica IL, et al. canSAR: update to the cancer translational research and drug discovery knowledgebase. Nucleic Acids Res. 2021;49:D1074\u201382.","journal-title":"Nucleic Acids Res"},{"key":"7587_CR32","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1002\/hep.23769","volume":"52","author":"S Senturk","year":"2010","unstructured":"Senturk S, Mumcuoglu M, Gursoy-Yuzugullu O, Cingoz B, Akcali KC, Ozturk M. Transforming growth factor-beta induces senescence in hepatocellular carcinoma cells and inhibits tumor growth. Hepatology. 2010;52:966\u201374.","journal-title":"Hepatology"},{"key":"7587_CR33","first-page":"3506","volume":"19","author":"LJ Zhu","year":"2020","unstructured":"Zhu LJ, Pan Y, Chen XY, Hou PF. BUB1 promotes proliferation of liver cancer cells by activating SMAD2 phosphorylation. Oncol Lett. 2020;19:3506\u201312.","journal-title":"Oncol Lett"},{"key":"7587_CR34","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.tibs.2010.08.004","volume":"36","author":"VM Bolanos-Garcia","year":"2011","unstructured":"Bolanos-Garcia VM, Blundell TL. BUB1 and BUBR1: multifaceted kinases of the cell cycle. Trends Biochem Sci. 2011;36:141\u201350.","journal-title":"Trends Biochem Sci"},{"key":"7587_CR35","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1016\/S0002-9440(10)62492-3","volume":"166","author":"GJ Gordon","year":"2005","unstructured":"Gordon GJ, Rockwell GN, Jensen RV, Rheinwald JG, Glickman JN, Aronson JP, et al. Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling. Am J Pathol. 2005;166:1827\u201340.","journal-title":"Am J Pathol"},{"key":"7587_CR36","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/ng.855","volume":"43","author":"M Bott","year":"2011","unstructured":"Bott M, Brevet M, Taylor BS, Shimizu S, Ito T, Wang L, et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet. 2011;43:668\u201372.","journal-title":"Nat Genet"},{"key":"7587_CR37","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1158\/1078-0432.CCR-12-2117","volume":"19","author":"A De Rienzo","year":"2013","unstructured":"De Rienzo A, Richards WG, Yeap BY, Coleman MH, Sugarbaker PE, Chirieac LR, et al. Sequential binary gene ratio tests define a novel molecular diagnostic strategy for malignant pleural mesothelioma. Clin Cancer Res. 2013;19:2493\u2013502.","journal-title":"Clin Cancer Res"},{"key":"7587_CR38","doi-asserted-by":"publisher","first-page":"565","DOI":"10.3390\/cancers13030565","volume":"13","author":"A De Rienzo","year":"2021","unstructured":"De Rienzo A, Coleman MH, Yeap BY, Severson DT, Wadowski B, Gustafson CE, et al. Association of RERG expression with female survival advantage in malignant pleural mesothelioma. Cancers. 2021;13:565.","journal-title":"Cancers"},{"key":"7587_CR39","doi-asserted-by":"publisher","first-page":"8334","DOI":"10.1073\/pnas.0703164104","volume":"104","author":"OV Gjoerup","year":"2007","unstructured":"Gjoerup OV, Wu J, Chandler-Militello D, Williams GL, Zhao J, Schaffhausen B, et al. Surveillance mechanism linking Bub1 loss to the p53 pathway. Proc Natl Acad Sci USA. 2007;104:8334\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"7587_CR40","doi-asserted-by":"publisher","first-page":"ra1","DOI":"10.1126\/scisignal.2005379","volume":"8","author":"S Nyati","year":"2015","unstructured":"Nyati S, Schinske-Sebolt K, Pitchiaya S, Chekhovskiy K, Chator A, Chaudhry N, et al. The kinase activity of the Ser\/Thr kinase BUB1 promotes TGF-\u03b2 signaling. Sci Signal. 2015;8:ra1.","journal-title":"Sci Signal"},{"key":"7587_CR41","doi-asserted-by":"publisher","first-page":"8159","DOI":"10.1002\/cam4.3411","volume":"9","author":"J Qiu","year":"2020","unstructured":"Qiu J, Zhang S, Wang P, Wang H, Sha B, Peng H, et al. BUB1B promotes hepatocellular carcinoma progression via activation of the mTORC1 signaling pathway. Cancer Med. 2020;9:8159\u201372.","journal-title":"Cancer Med"},{"key":"7587_CR42","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646\u201374.","journal-title":"Cell"},{"key":"7587_CR43","doi-asserted-by":"publisher","first-page":"12216","DOI":"10.3390\/ijms222212216","volume":"22","author":"V Ramundo","year":"2021","unstructured":"Ramundo V, Zanirato G, Aldieri E. The epithelial-to-mesenchymal transition (EMT) in the development and metastasis of malignant pleural mesothelioma. Int J Mol Sci. 2021;22:12216.","journal-title":"Int J Mol Sci"},{"key":"7587_CR44","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.ejcts.2009.08.027","volume":"37","author":"A Schramm","year":"2010","unstructured":"Schramm A, Opitz I, Thies S, Seifert B, Moch H, Weder W, et al. Prognostic significance of epithelial-mesenchymal transition in malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2010;37:566\u201372.","journal-title":"Eur J Cardiothorac Surg"},{"key":"7587_CR45","doi-asserted-by":"crossref","unstructured":"Foty R. A simple hanging drop cell culture protocol for generation of 3D spheroids. J Vis Exp. 2011;51:2720.","DOI":"10.3791\/2720-v"},{"key":"7587_CR46","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1093\/annonc\/mdu127","volume":"25","author":"MB Suraokar","year":"2014","unstructured":"Suraokar MB, Nunez MI, Diao L, Chow CW, Kim D, Behrens C, et al. Expression profiling stratifies mesothelioma tumors and signifies deregulation of spindle checkpoint pathway and microtubule network with therapeutic implications. Ann Oncol. 2014;25:1184\u201392.","journal-title":"Ann Oncol"},{"key":"7587_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/19768354.2021.1884599","volume":"25","author":"T Kim","year":"2021","unstructured":"Kim T, Gartner A. Bub1 kinase in the regulation of mitosis. Anim Cells Syst. 2021;25:1\u201310.","journal-title":"Anim Cells Syst"},{"key":"7587_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15822","volume":"8","author":"G Zhang","year":"2017","unstructured":"Zhang G, Kruse T, L\u00f3pez-M\u00e9ndez B, Sylvestersen KB, Garvanska DH, Schopper S, et al. Bub1 positions Mad1 close to KNL1 MELT repeats to promote checkpoint signalling. Nat Commun. 2017;8. 15822.","journal-title":"Nat Commun"},{"key":"7587_CR49","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1242\/jcs.059501","volume":"123","author":"D Perera","year":"2010","unstructured":"Perera D, Taylor SS. Sgo1 establishes the centromeric cohesion protection mechanism in G2 before subsequent Bub1-dependent recruitment in mitosis. J Cell Sci. 2010;123:653\u20139.","journal-title":"J Cell Sci"},{"key":"7587_CR50","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.molcel.2004.09.031","volume":"16","author":"Z Tang","year":"2004","unstructured":"Tang Z, Shu H, Oncel D, Chen S, Yu H. Phosphorylation of Cdc20 by Bub1 provides a catalytic mechanism for APC\/C inhibition by the spindle checkpoint. Mol Cell. 2004;16:387\u201397.","journal-title":"Mol Cell"},{"key":"7587_CR51","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/nrc.2017.42","volume":"17","author":"TA Yap","year":"2017","unstructured":"Yap TA, Aerts JG, Popat S, Fennell DA. Novel insights into mesothelioma biology and implications for therapy. Nat Rev Cancer. 2017;17:475\u201388.","journal-title":"Nat Rev Cancer"},{"key":"7587_CR52","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ejphar.2018.07.034","volume":"834","author":"YT Lee","year":"2018","unstructured":"Lee YT, Tan YJ, Oon CE. Molecular targeted therapy: treating cancer with specificity. Eur J Pharmacol. 2018;834:188\u201396.","journal-title":"Eur J Pharmacol"},{"key":"7587_CR53","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/nrd.2016.238","volume":"16","author":"C Fellmann","year":"2017","unstructured":"Fellmann C, Gowen BG, Lin PC, Doudna JA, Corn JE. Cornerstones of CRISPR-Cas in drug discovery and therapy. Nat Rev Drug Discov. 2017;16:89\u2013100.","journal-title":"Nat Rev Drug Discov"},{"key":"7587_CR54","first-page":"135","volume":"3","author":"J Cicenas","year":"2015","unstructured":"Cicenas J, Kalyan K, Sorokinas A, Stankunas E, Levy J, Meskinyte I, et al. Roscovitine in cancer and other diseases. Ann Transl Med. 2015;3:135.","journal-title":"Ann Transl Med"},{"key":"7587_CR55","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/cas.16070","volume":"115","author":"M Fukuoka","year":"2024","unstructured":"Fukuoka M, Kodama T, Murai K, Hikita H, Sometani E, Sung J, et al. Genome-wide loss-of-function genetic screen identifies INSIG2 as the vulnerability of hepatitis B virus-integrated hepatoma cells. Cancer Sci. 2024;115:859\u201370.","journal-title":"Cancer Sci"},{"key":"7587_CR56","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3389\/fbioe.2020.00268","volume":"8","author":"N Zhao","year":"2020","unstructured":"Zhao N, Guo M, Wang K, Zhang C, Liu X. Identification of pan-cancer prognostic biomarkers through integration of multi-omics data. Front Bioeng Biotechnol. 2020;8:268.","journal-title":"Front Bioeng Biotechnol"},{"key":"7587_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01305-3","volume":"20","author":"R Du","year":"2021","unstructured":"Du R, Huang C, Liu K, Li X, Dong Z. Targeting AURKA in cancer: molecular mechanisms and opportunities for cancer therapy. Mol Cancer. 2021;20. 15.","journal-title":"Mol Cancer"},{"key":"7587_CR58","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.ccell.2020.12.008","volume":"39","author":"L Chang","year":"2021","unstructured":"Chang L, Ruiz P, Ito T, Sellers WR. Targeting pan-essential genes in cancer: challenges and opportunities. Cancer Cell. 2021;39:466\u201379.","journal-title":"Cancer Cell"},{"key":"7587_CR59","doi-asserted-by":"publisher","DOI":"10.1093\/narcan\/zcac024","volume":"4","author":"E Lorenzini","year":"2022","unstructured":"Lorenzini E, Torricelli F, Zamponi R, Donati B, Manicardi V, Sauta E, et al. KAP1 is a new non-genetic vulnerability of malignant pleural mesothelioma (MPM). NAR Cancer. 2022;4. zcac024.","journal-title":"NAR Cancer"},{"key":"7587_CR60","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1038\/s41416-022-01979-0","volume":"127","author":"S Hiltbrunner","year":"2022","unstructured":"Hiltbrunner S, Fleischmann Z, Sokol ES, Zoche M, Felley-Bosco E, Curioni-Fontecedro A. Genomic landscape of pleural and peritoneal mesothelioma tumours. Br J Cancer. 2022;127:1997\u20132005.","journal-title":"Br J Cancer"},{"key":"7587_CR61","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.gene.2019.02.081","volume":"701","author":"J Piao","year":"2019","unstructured":"Piao J, Zhu L, Sun J, Li N, Dong B, Yang Y, et al. High expression of CDK1 and BUB1 predicts poor prognosis of pancreatic ductal adenocarcinoma. Gene. 2019;701:15\u201322.","journal-title":"Gene"},{"key":"7587_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/srep15993","volume":"5","author":"JY Han","year":"2015","unstructured":"Han JY, Han YK, Park GY, Kim SD, Lee CG. Bub1 is required for maintaining cancer stem cells in breast cancer cell lines. Sci Rep. 2015;5:15993.","journal-title":"Sci Rep"},{"key":"7587_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e16996","volume":"9","author":"J Zhang","year":"2023","unstructured":"Zhang J, Wei W, Zhong Q, Feng K, Yang R, Jiang Q. Budding uninhibited by benzimidazoles 1 promotes cell proliferation, invasion, and epithelial-mesenchymal transition via the Wnt\/\u03b2-catenin signaling in glioblastoma. Heliyon. 2023;9:e16996.","journal-title":"Heliyon"},{"key":"7587_CR64","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1002\/tox.23812","volume":"38","author":"W Jiang","year":"2023","unstructured":"Jiang W, Yu Y, Bhandari A, Hirachan S, Dong X, Huang X, et al. Budding uninhibited by benzimidazoles 1 might be a poor prognosis biomarker promoting the progression of papillary thyroid cancer. Environ Toxicol. 2023;38:2047\u201356.","journal-title":"Environ Toxicol"},{"key":"7587_CR65","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.997842","volume":"13","author":"X Mengyan","year":"2022","unstructured":"Mengyan X, Kun D, Xinming J, Yutian W, Yongqian S. Identification and verification of hub genes associated with the progression of non-small cell lung cancer by integrated analysis. Front Pharmacol. 2022;13:997842.","journal-title":"Front Pharmacol"},{"key":"7587_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/19768354.2021.1884599","volume":"25","author":"T Kim","year":"2021","unstructured":"Kim T, Gartner A. Bub1 kinase in the regulation of mitosis. Animal Cells Syst. 2021;25:1\u201310.","journal-title":"Animal Cells Syst"},{"key":"7587_CR67","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.cell.2014.06.029","volume":"158","author":"NJ Ganem","year":"2014","unstructured":"Ganem NJ, Cornils H, Chiu SY, O\u2019Rourke KP, Arnaud J, Yimlamai D, et al. Cytokinesis failure triggers hippo tumor suppressor pathway activation. Cell. 2014;158:833\u201348.","journal-title":"Cell"},{"key":"7587_CR68","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2020104419","volume":"39","author":"N H\u00e9garat","year":"2020","unstructured":"H\u00e9garat N, Crncec A, Suarez Peredo Rodriguez MF, Echegaray Iturra F, Gu Y, Busby O, et al. Cyclin A triggers mitosis either via the greatwall kinase pathway or Cyclin B. EMBO J. 2020;39:e104419.","journal-title":"EMBO J"},{"key":"7587_CR69","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1038\/onc.2014.133","volume":"34","author":"NN Kreis","year":"2015","unstructured":"Kreis NN, Louwen F, Yuan J. Less understood issues: p21(Cip1) in mitosis and its therapeutic potential. Oncogene. 2015;34:1758\u201367.","journal-title":"Oncogene"},{"key":"7587_CR70","doi-asserted-by":"publisher","first-page":"4534","DOI":"10.21037\/tcr-24-704","volume":"13","author":"R Zhou","year":"2024","unstructured":"Zhou R, Liu M, Li M, Peng Y, Zhang X. BUB1 as a novel marker for predicting the immunotherapy efficacy and prognosis of breast cancer. Transl Cancer Res. 2024;13:4534\u201354.","journal-title":"Transl Cancer Res"},{"key":"7587_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.107681","volume":"26","author":"MJ Martinez","year":"2023","unstructured":"Martinez MJ, Lyles RDZ, Peinetti N, Grunfeld AM, Burnstein KL. Inhibition of the serine\/threonine kinase BUB1 reverses taxane resistance in prostate cancer. iScience. 2023;26:107681.","journal-title":"iScience"},{"key":"7587_CR72","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/nprot.2013.143","volume":"8","author":"FA Ran","year":"2013","unstructured":"Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8:2281\u2013308.","journal-title":"Nat Protoc"},{"key":"7587_CR73","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1083\/jcb.201902048","volume":"218","author":"DG Nowak","year":"2019","unstructured":"Nowak DG, Katsenelson KC, Watrud KE, Chen M, Mathew G, D\u2019Andrea VD, et al. The PHLPP2 phosphatase is a druggable driver of prostate cancer progression. J Cell Biol. 2019;218:1943\u201357.","journal-title":"J Cell Biol"},{"key":"7587_CR74","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07901-8","volume":"9","author":"KR Sanson","year":"2018","unstructured":"Sanson KR, Hanna RE, Hegde M, Donovan KF, Strand C, Sullender ME, et al. Optimized libraries for CRISPR-Cas9 genetic screens with multiple modalities. Nat Commun. 2018;9:5416.","journal-title":"Nat Commun"},{"key":"7587_CR75","doi-asserted-by":"publisher","first-page":"10","DOI":"10.14806\/ej.17.1.200","volume":"17","author":"M Martin","year":"2011","unstructured":"Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet j. 2011;17:10.","journal-title":"EMBnet j"},{"key":"7587_CR76","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/s41596-018-0113-7","volume":"14","author":"B Wang","year":"2019","unstructured":"Wang B, Wang M, Zhang W, Xiao T, Chen CH, Wu A, et al. Integrative analysis of pooled CRISPR genetic screens using MAGeCKFlute. Nat Protoc. 2019;14:756\u201380.","journal-title":"Nat Protoc"},{"key":"7587_CR77","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06676-2","volume":"9","author":"K Szlachta","year":"2018","unstructured":"Szlachta K, Kuscu C, Tufan T, Adair SJ, Shang S, Michaels AD, et al. CRISPR knockout screening identifies combinatorial drug targets in pancreatic cancer and models cellular drug response. Nat Commun. 2018;9:4275.","journal-title":"Nat Commun"},{"key":"7587_CR78","unstructured":"DepMap B. This DepMap release contains data from CRISPR knockout screens from project Achilles, as well as genomic characterization data from the CCLE project. For more information, please see README.txt. figshare. 2023 [cited 2023 Dec 26]. p. 19462523936 Bytes. Available from: https:\/\/figshare.com\/articles\/dataset\/DepMap_23Q2_Public\/22765112\/2."},{"key":"7587_CR79","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nmeth.2089","volume":"9","author":"CA Schneider","year":"2012","unstructured":"Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9:671\u20135.","journal-title":"Nat Methods"},{"key":"7587_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.121690","volume":"323","author":"A Kurden-Pekmezci","year":"2023","unstructured":"Kurden-Pekmezci A, Cakiroglu E, Eris S, Mazi FA, Coskun-Deniz OS, Dalgic E, et al. MALT1 paracaspase is overexpressed in hepatocellular carcinoma and promotes cancer cell survival and growth. Life Sci. 2023;323. 121690.","journal-title":"Life Sci"},{"key":"7587_CR81","doi-asserted-by":"publisher","first-page":"973576","DOI":"10.3389\/fonc.2022.973576","volume":"12","author":"H Shi","year":"2022","unstructured":"Shi H, Rath EM, Lin RCY, Sarun KH, Clarke CJ, McCaughan BC, et al. 3-Dimensional mesothelioma spheroids provide closer to natural pathophysiological tumor microenvironment for drug response studies. Front Oncol. 2022;12:973576.","journal-title":"Front Oncol"},{"key":"7587_CR82","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1038\/s41374-018-0057-0","volume":"98","author":"DK Meyerholz","year":"2018","unstructured":"Meyerholz DK, Beck AP. Principles and approaches for reproducible scoring of tissue stains in research. Lab Invest. 2018;98:844\u201355.","journal-title":"Lab Invest"},{"key":"7587_CR83","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/j.cub.2021.01.062","volume":"31","author":"KSK Uchida","year":"2021","unstructured":"Uchida KSK, Jo M, Nagasaka K, Takahashi M, Shindo N, Shibata K, et al. Kinetochore stretching-mediated rapid silencing of the spindle-assembly checkpoint required for failsafe chromosome segregation. Curr Biol. 2021;31:1581\u201391.e3.","journal-title":"Curr Biol"},{"key":"7587_CR84","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1093\/nar\/30.1.207","volume":"30","author":"R Edgar","year":"2002","unstructured":"Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002;30:207\u201310.","journal-title":"Nucleic Acids Res"},{"key":"7587_CR85","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-019-1186-3","volume":"569","author":"M Ghandi","year":"2019","unstructured":"Ghandi M, Huang FW, Jan\u00e9-Valbuena J, Kryukov GV, Lo CC, McDonald ER, et al. Next-generation characterization of the cancer cell line encyclopedia. Nature. 2019;569:503\u20138.","journal-title":"Nature"},{"key":"7587_CR86","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"key":"7587_CR87","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-12-77","volume":"12","author":"X Robin","year":"2011","unstructured":"Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinforma. 2011;12:77.","journal-title":"BMC Bioinforma"},{"key":"7587_CR88","doi-asserted-by":"publisher","first-page":"733","DOI":"10.15252\/msb.20145216","volume":"10","author":"T Hart","year":"2014","unstructured":"Hart T, Brown KR, Sircoulomb F, Rottapel R, Moffat J. Measuring error rates in genomic perturbation screens: gold standards for human functional genomics. Mol Syst Biol. 2014;10:733.","journal-title":"Mol Syst Biol"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07587-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07587-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07587-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T00:28:26Z","timestamp":1743812906000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07587-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,3]]},"references-count":88,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7587"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-07587-z","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,3]]},"assertion":[{"value":"23 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"241"}}